BVF INC/IL
Q1 2014 13F-HR Holdings
Net value change ($000)
+73,532
(12.9%)
New positions
4
Sold out positions
3
Turnover %
3.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| FIVE PRIME THERAPEUTICS, INC. | 14,594 | 188.6% |
| REGADO BIOSCIENCES INC | 12,858 | 162.5% |
| ONCOTHYREON INC | 11,072 | 69.9% |
| RECEPTOS, INC. | 9,726 | 105.9% |
| ChemoCentryx, Inc. | 6,549 | 14.5% |
| TARGACEPT INC COM | 3,703 | 14.5% |
| IRWD | 3,440 | 3.1% |
| LGND | 2,869 | 2.1% |
| TREVENA INC | 2,751 | NEW |
| *BIOTA PHARMACEUTIALS INC | 2,663 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| CYTK | -14,394 | -93.5% |
| RIGL | -12,640 | -55.8% |
| XNCR | -7,495 | -100.0% |
| ARQULE INC | -1,051 | -17.3% |
| BIND THERAPEUTICS INC | -877 | -38.7% |
| Mirati Therapeutics, Inc. | -806 | -36.1% |
| Kindred Biosciences, Inc. | -577 | -100.0% |
| PTNT | -361 | -9.5% |
| SOPHIRIS BIO INC. | -222 | -10.0% |
| Regulus Therapeutics Inc. | -58 | -3.4% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
45,068
(7.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|